文献速递眼底病与葡萄膜炎小儿眼科与斜弱视青光眼

儿童特发性中间葡萄膜炎的长期结局

Long-Term Outcomes of Pediatric Idiopathic Intermediate Uveitis.
PubMed 文献 · Am J Ophthalmol · 2021-11-13

这项回顾性临床队列研究纳入125例16岁及以下的儿童特发性中间葡萄膜炎患者(221只眼),中位随访57个月。末次随访时116例(92.8%)患者最佳矫正视力达20/40或更好且葡萄膜炎静止,但未使用保类固醇类免疫调节剂是发生新发黄斑水肿和青光眼的最强预测因素。

要点

  • 末次随访时116例(92.8%)患者最佳矫正视力达20/40或更好且葡萄膜炎静止。
  • 未使用保类固醇类免疫调节剂是新发黄斑水肿(OR=6.3)和青光眼(OR=6.6)的最强预测因素。
  • 最常见的并发症为眼压升高(65只眼,29.4%)、白内障(41只眼,18.5%)和囊样黄斑水肿(29只眼,13.1%)。

核心结论

  • 儿童特发性中间葡萄膜炎的视力结局良好,但威胁视力的炎症后遗症发生频率高,带来终身进一步视力丧失的风险。
  • 使用免疫调节治疗与发生黄斑水肿和眼压升高的风险较低相关。

研究设计与样本

  • 回顾性临床队列研究,在机构环境中开展,纳入125例16岁及以下儿童(221只眼)。
  • 分析变量包括就诊时年龄和临床发现、治疗及随访时长,采用多变量分析探究结局的潜在预测因素。

主要发现

  • 中位随访57个月;就诊时11只眼(4.4%)最佳矫正视力差于20/160,35只眼(14%)有明显玻璃体混浊(≥2+标准葡萄膜炎命名法(SUN))。
  • 41例儿童(33%)使用保类固醇类药物,最常用为甲氨蝶呤(27例儿童,21.6%)。
  • 最常见的并发症为眼压升高(n=65;29.4%)、白内障(n=41;18.5%)和囊样黄斑水肿(n=29;13.1%)。
  • 末次随访时116例(92.8%)患者最佳矫正视力达20/40或更好且葡萄膜炎静止。
  • 未使用保类固醇类免疫调节剂是观察期间新发黄斑水肿(比值比=6.3,95%CI=2.3-16.9,P<.001)或青光眼(比值比=6.6,95%CI=2.5-17.9,P<.001)的最强预测因素。

关键数值与推荐

  • 儿童特发性中间葡萄膜炎的诊断基于无相关系统性疾病。
  • 玻璃体混浊严重程度采用标准葡萄膜炎命名法(SUN)分级,显著混浊定义为≥2+。
  • 未使用保类固醇类免疫调节剂与新发黄斑水肿(OR=6.3,95%CI=2.3-16.9,P<.001)和青光眼(OR=6.6,95%CI=2.5-17.9,P<.001)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the course of childhood-onset intermediate uveitis without associated systemic disease, and investigate determinants of outcomes. DESIGN: A retrospective clinical cohort study METHODS: This study was conducted in an institutional setting. A total of 125 children (221 eyes) aged 16 years and less participated. Outcomes of interest were visual acuity, severity of inflammation, and the occurrence of sight-threatening complications. Variables examined included age and clinical findings at presentation, treatment, and duration of follow-up. Multivariable analysis was undertaken to investigate potential predictors of outcomes. RESULTS: The median follow-up duration was 57 months. At presentation, best-corrected visual acuity worse than 20/160 was recorded in 11 (4.4%) eyes and significant vitreous haze (≥2+Standardisation of Uveitis Nomenclature (SUN)) in 35 (14%) eyes. Corticosteroid-sparing agents were used in 41 children (33%), with methotrexate most commonly used (27 children, 21.6%). The most frequent complications were raised intraocular pressure (n = 65; 29.4%), cataract (n = 41; 18.5%), and cystoid macular edema (n = 29; 13.1%). At the last visit, 116 (92.8%) patients achieved best-corrected vision of 20/40 or better with quiescent uveitis. The absence of the use of a steroid-sparing immunomodulatory agent was the strongest predictive factor for the development of new macular edema (odds ratio = 6.3, 95% CI = 2.3-16.9, P < .001) or glaucoma (odds ratio = 6.6, 95% CI = 2.5-17.9, P < .001) over the period of observation. CONCLUSIONS: The visual outcomes of childhood-onset idiopathic intermediate uveitis are favorable. The frequency of sight-threatening sequelae of inflammation, which confer a lifelong risk of further visual loss, is high. The use of immunomodulatory therapy is associated with a lower risk of developing macular edema and ocular hypertension.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. AlBloushi AF, Solebo AL, Gokhale E, et al. Long-Term Outcomes of Pediatric Idiopathic Intermediate Uveitis. Am J Ophthalmol. 2021. PMID: 34780797. doi:10.1016/j.ajo.2021.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。